The groundbreaking rise of Viagra has long been a benchmark of pharmaceutical success, yet its legacy within the broader sector now triggers questions about long-term returns . Generic versions are diminishing patent protection , prompting concerns that supporting companies significantly dependent to Viagra's previous influence could be a dangerous